Search Details

Word: humulin (lookup in dictionary) (lookup stats)
Dates: all
Sort By: most recent first (reverse)


Usage:

...that they can work the same magic in the marketplace, turning those wonder drugs into profitmakers. Last week Genentech, an industry leader based in south San Francisco, began selling its first drug product for humans: Protropin, a growth hormone used to treat dwarfism in children. Genentech had previously developed Humulin, a synthetic insulin, but licensed it to an established pharmaceutical company, Eli Lilly, which put the drug on the market. Protropin, which is expected to generate annual sales of $40 million, is the first human drug that a new biotech company has tried to sell on its own. Says Robert...

Author: /time Magazine | Title: Going for the Gene Green | 4/18/2005 | See Source »

...every new product immediately finds a big market. In July, Eli Lilly began U.S. commercial production of synthetic human insulin. The drug, Humulin, has about the same effects as conventional insulin and costs just as much or more (about 50? a dose). Nonetheless, Eli Lilly still has hopes for major sales...

Author: /time Magazine | Title: Hoping to Clone Some Profits | 2/27/1984 | See Source »

...Humulin represents only a small advance for an American industry that has produced scant profits for its backers and worldwide sales of just $25 million. Another form of human insulin, made conventionally through chemical processes by Denmark's Novo Industri, has been on the market in Great Britain since June. Though Humulin's cost will decline as production runs increase, it will initially be twice as expensive as animal-based insulin and its eventual market is limited, no more than $20 million...

Author: /time Magazine | Title: Artificial Genes | 11/15/1982 | See Source »

...Since Humulin has been licensed to giant Eli Lilly & Co. for production and sale as a nonprescription drug, Genentech stands to make at most 10% of any profits. Says Analyst Marilyn Hill of Arthur D. Little in Cambridge, Mass.: "Royalties and fees are not going to make these companies a big success. Genentech still has to show that it can develop its marketing clout with its own products." Investors apparently agree. Although Genentech's stock ran up from $33 a share to $46 in the weeks preceding the announcement, it is well below the fantastic $89 it briefly...

Author: /time Magazine | Title: Artificial Genes | 11/15/1982 | See Source »

Still, gene splicing shows promise of living up to most of the extravagant claims made by its supporters, who expect it to reap sales of $25 billion by the year 2000. One of the most encouraging signs is the quick action by the FDA, which licensed Humulin after just five months of testing, one of the quickest approvals in the agency's history. Genentech President Robert Swanson said last week that his company expects to market a number of other new products in the next few years, including an agent that dissolves blood clots and could be useful...

Author: /time Magazine | Title: Artificial Genes | 11/15/1982 | See Source »

| 1 | 2 | Next